-+ 0.00%
-+ 0.00%
-+ 0.00%

Definium Therapeutics publishes corporate presentation outlining DT120 ODT clinical development pipeline in mental health indications

PUBT·08/13/2026 20:20:05
Listen to the news
Definium Therapeutics publishes corporate presentation outlining DT120 ODT clinical development pipeline in mental health indications
  • Definium outlined a late-stage program for DT120 ODT (lysergide) targeting generalized anxiety disorder, major depressive disorder, posttraumatic stress disorder.
  • Phase 3 Voyage in GAD met primary and key secondary endpoints; placebo-adjusted HAM-A improvement 5.4 points at week 12 (p<0.0001).
  • Voyage also showed a 7.7-point placebo-adjusted HAM-A improvement at week 1 (p<0.0001), indicating rapid symptom reduction.
  • Topline data for Phase 3 Panorama in GAD are expected in September 2026; Phase 3 readouts in MDD are targeted in 2027.
  • Safety and delivery model highlighted single-dose sessions with about 6 hours to end-of-session clearance; about 1.7% serious adverse event rate across studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.